Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Stock Information for Lisata Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lisata Therapeutics Inc.

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year'
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.